Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
08:05am, Wednesday, 13'th Mar 2024
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results.
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO ANNOUNCES DATA FROM PROPRIETARY NEUROTROPIC AAV CAPSID DEMONSTRATING INDUSTRY-LEADING BLOOD-BRAIN BARRIER PENETRATION & BRAIN TRANSDUCTION.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast
06:30pm, Tuesday, 12'th Mar 2024
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast.
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES U.S. FDA ALIGNMENT ON ABBREVIATED PATHWAY TO POTENTIAL APPROVAL AND EMA PRIME ELIGIBILITY FOR ST-920 IN FABRY DISEASE.
RICHMOND, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES UPDATED PHASE 1/2 STAAR STUDY DATA IN FABRY DISEASE SHOWING SUSTAINED BENEFIT AND DIFFERENTIATED SAFETY PROFILE.
2 low-priced gene therapy stocks to speculate on
08:26am, Monday, 08'th Jan 2024
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic differences.
Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript
11:51am, Thursday, 02'nd Nov 2023
Sangamo Therapeutics, Inc. (SGMO) Q3 2023 Earnings Call Transcript
Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results
04:01pm, Wednesday, 01'st Nov 2023
BRISBANE, Calif.--(BUSINESS WIRE)--SANGAMO THERAPEUTICS ANNOUNCES STRATEGIC UPDATE AND REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS.
Sangamo Therapeutics (SGMO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
11:22am, Thursday, 26'th Oct 2023
Sangamo (SGMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast
04:15pm, Wednesday, 25'th Oct 2023
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics Announces Third Quarter 2023 Conference Call and Webcast.
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present Pre-Clinical Data Showcasing its Epigenetic Regulation for Neurology and CAR-Treg Research at ESGCT.
Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit
04:15pm, Wednesday, 20'th Sep 2023
BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit.
Sangamo Therapeutics: Recent Updates Bolster My Long-Term Conviction
05:36am, Friday, 08'th Sep 2023
Sangamo Therapeutics has faced challenges in recent years but has made moves and closed deals that have reignited interest in the company. The company has provided updates on its pipeline progress, in
Untapped Potential: 3 Stocks Tackling the Toughest Rare Diseases
01:38pm, Friday, 25'th Aug 2023
Rare disease stocks have a difficult task. The rarer a disease is, the less public research goes into studying it.
Sangamo Therapeutics (SGMO) Reports Q2 Loss, Misses Revenue Estimates
06:56pm, Tuesday, 08'th Aug 2023
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.29 per share a year ago.
